CagriSema: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Expected to follow semaglutide storage guidelines. Store refrigerated at 2-8 degrees C. Do not freeze. Specific storage conditions will be defined in prescribing information upon regulatory approval.
Protocol Quick-Reference
Chronic weight management in adults with obesity or overweight
Dosing
Amount
Cagrilintide 2.4 mg + semaglutide 2.4 mg
Frequency
Once weekly
Duration
68 weeks (Phase 3 trials)
Administration
Route
SCSchedule
Once weekly
Timing
Single injection from pre-filled pen combining both agents. Gradual dose escalation over 16-20 weeks to reach target maintenance dose. Inject on the same day each week, any time of day, without regard to meals.
Cycle
Duration
Ongoing (long-term use intended)
Repeatable
Yes
โ๏ธ Suggested Bloodwork (4 tests)
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Baseline liver and kidney function
HbA1c
When: Baseline
Why: Baseline glycemic status
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk assessment
HbA1c and lipid panel
When: 16 weeks
Why: Monitor metabolic improvements after reaching maintenance dose
๐ก Key Considerations
- โNot yet FDA-approved: NDA filed in 2025, regulatory decision expected in 2026
- โGI side effects are common (79.6% in CagriSema group): dose escalation is required to minimize
- โNo cardiovascular outcomes data yet available
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Obesity / Weight Management (REDEFINE 1 trial protocol) | Once-weekly subcutaneous injection. Target maintenance dose is cagrilintide 2.4 mg plus semaglutide 2.4 mg. Gradual dose escalation over approximately 16-20 weeks to reach target maintenance dose. | Once weekly subcutaneous injection | 68 weeks in Phase 3 trials; intended for long-term use | Co-administered as a single injection from a pre-filled pen. Dose escalation is required for both components to minimize GI side effects. Not yet FDA-approved. |
| Type 2 Diabetes with Obesity (REDEFINE 2 trial protocol) | Once-weekly subcutaneous injection. Target dose is cagrilintide 2.4 mg plus semaglutide 2.4 mg. Same dose escalation schedule as REDEFINE 1. | Once weekly subcutaneous injection | 68 weeks in Phase 3 trial | Produced 13.7% weight loss and HbA1c reductions with 73.5% achieving HbA1c of 6.5% or less. Background diabetes medications may need dose adjustment. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
CagriSema is supplied as a pre-filled pen device containing both cagrilintide and semaglutide in a single formulation. No reconstitution, mixing, or dilution is required.
Recommended Injection Sites
- โAbdomen (at least 2 inches from navel)
- โFront of thigh (middle third)
- โUpper arm (back, upper outer area)
๐งStorage Requirements
Expected to follow semaglutide storage guidelines. Store refrigerated at 2-8 degrees C. Do not freeze. Specific storage conditions will be defined in prescribing information upon regulatory approval.
Community Dosing Protocols
Compare these clinical doses with what 15+ community members report using.
Based on 15+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
CagriSema is an investigational medication with an NDA filed but not yet approved by the FDA. All dosing information is derived from published clinical trial protocols. Dosing should only occur under the supervision of qualified healthcare providers.
Clinical Trial Dosing#
Target Dose#
The target maintenance dose used in Phase 3 REDEFINE trials is cagrilintide 2.4 mg plus semaglutide 2.4 mg, administered as a single once-weekly subcutaneous injection.
Dose Escalation#
Both cagrilintide and semaglutide require gradual dose escalation to minimize gastrointestinal adverse events. The CagriSema escalation protocol involves parallel up-titration of both components over approximately 16-20 weeks.
The semaglutide component follows a similar escalation to the established Wegovy schedule, while the cagrilintide component is also gradually increased. The matched escalation allows both peptides to reach their full 2.4 mg doses simultaneously.
Clinical Outcomes by Trial#
REDEFINE 1 (68 weeks, obesity without diabetes):
| Treatment | Mean Weight Loss | Achieving 20%+ Loss | Achieving 30%+ Loss |
|---|---|---|---|
| CagriSema 2.4/2.4 mg | 20.4% | 60% | 23% |
| Semaglutide 2.4 mg alone | 14.9% | -- | -- |
| Cagrilintide 2.4 mg alone | 11.5% | -- | -- |
| Placebo | 3.0% | -- | -- |
REDEFINE 2 (68 weeks, obesity with type 2 diabetes):
| Treatment | Mean Weight Loss | HbA1c 6.5% or Less |
|---|---|---|
| CagriSema 2.4/2.4 mg | 13.7% | 73.5% |
| Placebo | 3.4% | 15.9% |
Administration#
Injection Technique#
CagriSema is administered as a single subcutaneous injection using a pre-filled pen device. The injection technique follows standard procedures for subcutaneous peptide medications:
- Remove pen from refrigeration and allow to reach room temperature
- Select injection site (abdomen, thigh, or upper arm)
- Clean the injection site
- Administer subcutaneous injection
- Rotate injection sites weekly
Timing#
CagriSema is administered once weekly on the same day each week, at any time of day, without regard to meals. The dosing day may be changed as long as at least 2 days have elapsed since the last dose.
Storage#
As a peptide-based injectable, CagriSema is expected to require refrigerated storage (2-8 degrees C), consistent with semaglutide pen storage requirements. Detailed storage conditions will be specified in the prescribing information upon approval.
Comparison with Individual Components#
| Feature | CagriSema | Wegovy (Semaglutide) | Cagrilintide (monotherapy) |
|---|---|---|---|
| Dose | 2.4 mg / 2.4 mg | 2.4 mg | 2.4 mg |
| Frequency | Once weekly | Once weekly | Once weekly |
| Injections per week | 1 | 1 | 1 (investigational) |
| Weight loss | 20.4% | 14.9% | 11.5% |
| Route | Subcutaneous | Subcutaneous | Subcutaneous |
Dosing Context#
CagriSema belongs to the Metabolic category of research peptides. Dosing protocols for CagriSema are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for CagriSema:
Obesity / Weight Management (REDEFINE 1 trial protocol)#
Dose: Once-weekly subcutaneous injection. Target maintenance dose is cagrilintide 2.4 mg plus semaglutide 2.4 mg. Gradual dose escalation over approximately 16-20 weeks to reach target maintenance dose.
Frequency: Once weekly subcutaneous injection
Duration: 68 weeks in Phase 3 trials; intended for long-term use
Co-administered as a single injection from a pre-filled pen. Dose escalation is required for both components to minimize GI side effects. Not yet FDA-approved.
Type 2 Diabetes with Obesity (REDEFINE 2 trial protocol)#
Dose: Once-weekly subcutaneous injection. Target dose is cagrilintide 2.4 mg plus semaglutide 2.4 mg. Same dose escalation schedule as REDEFINE 1.
Frequency: Once weekly subcutaneous injection
Duration: 68 weeks in Phase 3 trial
Produced 13.7% weight loss and HbA1c reductions with 73.5% achieving HbA1c of 6.5% or less. Background diabetes medications may need dose adjustment.
Reconstitution and Preparation#
CagriSema is supplied as a pre-filled pen device containing both cagrilintide and semaglutide in a single formulation. No reconstitution, mixing, or dilution is required.
Injection Sites#
Recommended injection sites for CagriSema include:
- Abdomen (at least 2 inches from navel)
- Front of thigh (middle third)
- Upper arm (back, upper outer area)
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Expected to follow semaglutide storage guidelines. Store refrigerated at 2-8 degrees C. Do not freeze. Specific storage conditions will be defined in prescribing information upon regulatory approval.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About CagriSema
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.